The Rogosin Institute
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1983-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.rogosin.org/
Open-Label Phase 2 Efficacy Trial of Cancer Macrobeads in Patients With Treatment-Resistant Pancreatic/Colorectal Cancer
Phase 2
Completed
- Conditions
- Pancreatic Adenocarcinoma Non-resectablePancreatic Adenocarcinoma MetastaticColorectal Cancer Metastatic
- Interventions
- Biological: RENCA macrobeads
- First Posted Date
- 2010-01-21
- Last Posted Date
- 2021-05-12
- Lead Sponsor
- The Rogosin Institute
- Target Recruit Count
- 58
- Registration Number
- NCT01053013
- Locations
- 🇺🇸
Weill Cornell Medical Center / The Rogosin Institute, New York, New York, United States
Polycystic Kidney Disease Data Repository
Recruiting
- Conditions
- Polycystic Kidney Disease
- First Posted Date
- 2008-11-17
- Last Posted Date
- 2025-03-06
- Lead Sponsor
- The Rogosin Institute
- Target Recruit Count
- 1000
- Registration Number
- NCT00792155
- Locations
- 🇺🇸
The Rogosin Institute, New York, New York, United States
Combined Renin Inhibition/Beta-blockade
Not Applicable
Terminated
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2008-03-04
- Last Posted Date
- 2015-11-24
- Lead Sponsor
- The Rogosin Institute
- Target Recruit Count
- 1
- Registration Number
- NCT00627861
- Locations
- 🇺🇸
The Rogosin Institute, New York, New York, United States
Mouse Cancer Cell-containing Macrobeads in the Treatment of Human Cancer
Phase 1
Completed
- Conditions
- Intraabdominal Cancers (Various Types)
- Interventions
- Biological: Cancer Macrobead placement in abdominal cavity
- First Posted Date
- 2006-01-27
- Last Posted Date
- 2019-01-16
- Lead Sponsor
- The Rogosin Institute
- Target Recruit Count
- 56
- Registration Number
- NCT00283075
- Locations
- 🇺🇸
NewYork Presbyterian Weill Cornell Medical Center, New York, New York, United States
© Copyright 2025. All Rights Reserved by MedPath